key: cord-0835107-xdiqkzks authors: Abate, Filomena; Erro, Roberto; Barone, Paolo; Picillo, Marina title: Managing device‐aided treatments in Parkinson's disease in times of COVID‐19 date: 2020-05-16 journal: Mov Disord Clin Pract DOI: 10.1002/mdc3.12985 sha: fb10abe983e75638c0dacc24fb6f485674df7df8 doc_id: 835107 cord_uid: xdiqkzks nan We read with interest the viewpoint review from Fasano et al. on management of advanced therapies in Parkinson's Disease (PD) patients during COVID-19 pandemic [1] . We agree with the authors this crisis may be turned into an opportunity. Our national health care systems should actively support clinicians in the remote management of chronic neurological patients, including those with advanced PD. Similarly to other countries, outpatient clinics have been suspended in Italy. Although recommendations are available to implement telemedicine for movement disorder clinics, Italy still lacks of a formal national system for remote management of chronic patients, including dedicated emergency lines [2,3]. Thus, clinicians use alternative methods to ensure the most effective assistance to PD patients on advanced therapies. Herein, we share our experience on remote management of three cases of PD patients on device-aided therapies by whatsapp video and phone calls, also using neurologist's private phone number. First patient is 56-year-old man with an 8-year history of PD complicated by pathological gambling. Bilateral subthalamic nucleus deep brain stimulation (STN DBS) was performed in February 2020 (Vercise TM , Boston Scientific, Marlborough, MA, USA) and first programming was scheduled for March as per routine practice [4] . Since all routine visits were suspended due to COVID-19 emergency, first programming was scheduled on an urgent basis and several initiatives were run to maximize safety for both patient and neurologist. First, both wore surgical masks and, instead of rigidity, bradykinesia was chosen to evaluate stimulation efficacy to maintain the recommended social distancing. The bluetooth connection from the programmer to the patient' implanted pulse generator was helpful for this sake. Finally, a program for the upcoming weeks was proposed and the patient was trained on the use of the remote control [5] (Figure) . This article is protected by copyright. All rights reserved. Second patient was a 73-year-old man with a 10-year-history of PD and on intrajejunal infusion of levodopa/carbidopa intestinal gel (LCIG) since last year. On March 2020 his infusion pump stopped working properly likely due to obstruction of the PEG-J tube. Although PEG-J tube was washed repeatedly, the issue persisted. Thus, the patient was switched from LCIG to regular levodopa maintaining Levodopa equivalent dose stable (from LCIG 3.4 ml/h per 14 h/day to Levodopa/Carbidopa 250+25 mg 4 tablets/day) and continued to wash daily the PEG-J tube. After about one week he was able to switch back to LICG with no further complaints. Third patient is 70-year-old woman with a 7-year-history of PD with dementia and on LCIG since two years (2.6 ml/h for 12-14h/day). Due to recent worsening of a pre-existing abdominal tumor, she presented an aggravation of her general condition and severe dysphagia. Thus, patient's caregiver was suggested to use the PEG-J (15 Fr) for enteral nutrition through the gastric port. Her neurological condition has been stable since then. We provided few examples supporting the role of video and phone contacts also for management of emergencies in advanced therapies in PD. Such observations should prompt national and local health care system to support clinician in remote management of chronic patients. The usefulness of the patients' remote control for DBS management was also emphasized. On behalf of all authors, the corresponding author states that there are neither funding sources nor conflict of interest. This article is protected by copyright. All rights reserved. The study has been approved by the appropriate ethics committee and have therefore been This article is protected by copyright. All rights reserved. Management of Advanced Therapies in Parkinson's Disease Patients in times of Humanitarian crisis: the COVID-19 experience. Movement disorder clinical practice. 2020 Epub ahead of print 2. International Parkinson and Movement Disorder Society, Telemedicine study group Tele-health for patients with deep brain stimulation: The experience of the Ontario Telemedicine Network Programming Deep Brain Stimulation for Parkinson's Disease: The Toronto Western Hospital Algorithms Pre-established 4-week program for stimulation tuning and dopaminergic medication management. Medications were slowly titrated since the patient was at risk for side effects from dopaminergic deprivation given the history of pathological gambling. Medications at the beginning included: Levodopa/Carbidopa/Entacapone 100 mg 2/die, Levodopa/Carbidopa/Entacapone 75 mg 3/die, Levodopa/Carbidopa/Entacapone 50 mg 1/die, Rotigotine patch 4 mg/die, Melevodopa/Carbidopa 100+25 3c/die, Amantadine 100 mg 3/die. Lower section. Effective program was changed due to onset of dyskinesia, increase of sexual drive and gait freezing 3mA/60μs/130Hz 3mA/60μs/130Hz) with a significant reduction of levodopa equivalent daily dose (LEDD from 1152 to 600 mg)